Abstract
Antigens of infectious agents share amino acid sequences with human proteins. Such a peptide matching may lead to autoimmunity through crossreactivity phenomena following pathogen infection and/or immunotherapeutic approaches. In this framework, we analyzed as a model the primary sequence of human cytomegalovirus (HCMV) glycoprotein B (gB) protein and searched for viral peptide sequences shared with human proteins. We show that the HCMV antigen has a high peptide identity with a large number of human proteins at the penta-, hexa-, and heptapeptide level, with the viral versus human peptide overlap involving host proteins implicated in crucial processes such as embryonic development, spermatogenesis, spatial learning, and hippocampal plasticity, inter alia. This study might help understand the etiology of the pathologic sequela associated with HCMV (re)activation and, in addition, address scientific and clinical research toward the definition of antiviral therapeutics based on non-crossreactive viral sequences.
Keywords: Anti-HCMV immune response, autoimmune diseases, crossreactivity, HCMV glycoprotein B, human proteins, peptide sharing.
Current Drug Discovery Technologies
Title:Potential Crossreactivity of Human Immune Responses Against HCMV Glycoprotein B
Volume: 13 Issue: 1
Author(s): Guglielmo Lucchese and Darja Kanduc
Affiliation:
Keywords: Anti-HCMV immune response, autoimmune diseases, crossreactivity, HCMV glycoprotein B, human proteins, peptide sharing.
Abstract: Antigens of infectious agents share amino acid sequences with human proteins. Such a peptide matching may lead to autoimmunity through crossreactivity phenomena following pathogen infection and/or immunotherapeutic approaches. In this framework, we analyzed as a model the primary sequence of human cytomegalovirus (HCMV) glycoprotein B (gB) protein and searched for viral peptide sequences shared with human proteins. We show that the HCMV antigen has a high peptide identity with a large number of human proteins at the penta-, hexa-, and heptapeptide level, with the viral versus human peptide overlap involving host proteins implicated in crucial processes such as embryonic development, spermatogenesis, spatial learning, and hippocampal plasticity, inter alia. This study might help understand the etiology of the pathologic sequela associated with HCMV (re)activation and, in addition, address scientific and clinical research toward the definition of antiviral therapeutics based on non-crossreactive viral sequences.
Export Options
About this article
Cite this article as:
Lucchese Guglielmo and Kanduc Darja, Potential Crossreactivity of Human Immune Responses Against HCMV Glycoprotein B, Current Drug Discovery Technologies 2016; 13 (1) . https://dx.doi.org/10.2174/1568009616666160129100621
DOI https://dx.doi.org/10.2174/1568009616666160129100621 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Four Major Factors Regulate Phosphatidylinositol 3-kinase Signaling Pathway in Cancers Induced by Infection of Human Papillomaviruses
Current Medicinal Chemistry Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical Pharmacology
Current Drug Metabolism Combating P-glycoprotein-Mediated Multidrug Resistance Using Therapeutic Nanoparticles
Current Pharmaceutical Design The Vanilloid Agonist Resiniferatoxin for Interventional-Based Pain Control
Current Topics in Medicinal Chemistry Cancer Stem Cells: How can we Target them?
Current Medicinal Chemistry Recent Development of Copolymeric Nano-Drug Delivery System for Paclitaxel
Anti-Cancer Agents in Medicinal Chemistry Identification and Targeting of Tumor Escape Mechanisms: A New Hope for Cancer Therapy?
Current Pharmaceutical Design Looking at Drug Resistance Mechanisms for Microtubule Interacting Drugs: Does TUBB3 Work?
Current Cancer Drug Targets Current Advances in the Biological Activity of Polysaccharides in Dendrobium with Intriguing Therapeutic Potential
Current Medicinal Chemistry Proteasome Inhibitors in Cancer Therapy
Current Drug Targets Targeting Myc in Pediatric Malignancies of the Central and Peripheral Nervous System
Current Cancer Drug Targets Temporal Progression of Kainic Acid Induced Changes in Vascular Laminin Expression in Rat Brain with Neuronal and Glial Correlates
Current Neurovascular Research Vascular Endothelial Cell Growth Factor (VEGF), An Emerging Target for Cancer Chemotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment
Current Topics in Medicinal Chemistry Medicinal Compound Celastrol As a Potential Clinical Anticancer Drug: Lessons Learned From Preclinical Studies
Clinical Cancer Drugs Patenting Networking and Knowledge Translation in Liposomes for Cancer Therapy
Recent Patents on Nanomedicine Cancer Therapy By Targeting Hypoxia-Inducible Factor-1
Current Cancer Drug Targets Galectins: Major Signaling Modulators Inside and Outside the Cell
Current Molecular Medicine The Potential Role of Pharmacogenomic and Genomic in the Adjuvant Treatment of Early Stage Non Small Cell Lung Cancer
Current Genomics Minor-Groove Binding Agents: Rational Design of Carboxamide Bond Isosteres
Current Topics in Medicinal Chemistry